Positive Allosteric Modulation of mGluR5 by VU0409551 Attenuates Clinical Severity, Anxiety-like Behavior, and Persistent Neuroinflammation in Experimental Autoimmune Encephalomyelitis

Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of the central nervous system, characterized by progressive neurodegeneration and disability. Current disease-modifying therapies primarily target peripheral immune cells and show limited efficacy in halting relapse-independent long-term progression and the resulting neurodegeneration. The type 5 metabotropic glutamate receptor (mGluR5) has emerged as a promising therapeutic target due to its role in regulating neuroinflammation and cell survival. This study evaluated the therapeutic efficacy of VU0409551, a selective mGluR5 positive allosteric modulator (PAM), in the experimental autoimmune encephalomyelitis (EAE) mouse model, the most widely studied animal model of MS. Daily treatment with VU0409551 (10 mg/kg, intraperitoneally) significantly attenuated clinical disease severity and prevented characteristic body weight loss. Proteomic analyses revealed that VU0409551 treatment attenuated molecular signatures associated with immune responses. During remission, VU0409551 ameliorated EAE-associated anxiety-like behavior and attenuated persistent cortical neuroinflammatory alterations, including astrogliosis, microglial accumulation, and increased TNF expression. Notably, treatment also reduced signatures associated with astrocyte and oligodendrocyte reactivity, including C3, C4b, Serpina3n, and H2-D1. These findings demonstrate that VU0409551 exerts robust therapeutic effects, positioning it as a promising and novel disease-modifying candidate for MS.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-13
DOI
https://doi.org/10.3390/ijms272210179
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Positive Allosteric Modulation of mGluR5 by VU0409551 Attenuates Clinical Severity, Anxiety-like Behavior, and Persistent Neuroinflammation in Experimental Autoimmune Encephalomyelitis

Júlia S. Fahel, Luciene Bruno Vieira, Melissa T. Goulart, Frank Kjeldsen et al.
2 links
International Journal of Molecular Sciences
Multiple Sclerosis Research Studies
article

Positive Allosteric Modulation of mGluR5 by VU0409551 Attenuates Clinical Severity, Anxiety-like Behavior, and Persistent Neuroinflammation in Experimental Autoimmune Encephalomyelitis

Júlia S. Fahel, Luciene Bruno Vieira, Melissa T. Goulart, Frank Kjeldsen, Vladimir Gorshkov, Nathália Covre da Silva, Luiz G.P. dos Santos, Fabiola Mara Ribeiro, Pablo Leal Cardozo, Thiago Verano‐Braga, Esther M. A. Maciel, Júlia Rezende-Ribeiro, Thiago H. G. Mello, Juliana S. B. Oliveira, Emanuelle G. Silva, Juliana Fantin
article en

Abstract

Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating disease of the central nervous system, characterized by progressive neurodegeneration and disability. Current disease-modifying therapies primarily target peripheral immune cells and show limited efficacy in halting relapse-independent long-term progression and the resulting neurodegeneration. The type 5 metabotropic glutamate receptor (mGluR5) has emerged as a promising therapeutic target due to its role in regulating neuroinflammation and cell survival. This study evaluated the therapeutic efficacy of VU0409551, a selective mGluR5 positive allosteric modulator (PAM), in the experimental autoimmune encephalomyelitis (EAE) mouse model, the most widely studied animal model of MS. Daily treatment with VU0409551 (10 mg/kg, intraperitoneally) significantly attenuated clinical disease severity and prevented characteristic body weight loss. Proteomic analyses revealed that VU0409551 treatment attenuated molecular signatures associated with immune responses. During remission, VU0409551 ameliorated EAE-associated anxiety-like behavior and attenuated persistent cortical neuroinflammatory alterations, including astrogliosis, microglial accumulation, and increased TNF expression. Notably, treatment also reduced signatures associated with astrocyte and oligodendrocyte reactivity, including C3, C4b, Serpina3n, and H2-D1. These findings demonstrate that VU0409551 exerts robust therapeutic effects, positioning it as a promising and novel disease-modifying candidate for MS.

International Journal of Molecular SciencesVol. 27(22)
Universidade Federal de Minas Gerais (BR), Universidade Federal do Rio de Janeiro (BR), University of Southern Denmark (DK), Instituto de Biofísica Carlos Chagas Filho (BR)
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon